Invivogen
Menu

CL429 VacciGrade™

CL429 VacciGrade™ Unit size Cat. code Docs Qty Price
TLR2 & NOD2-based adjuvant
5 mg
vac-c429
+-
$570.00

Dual TLR2 & NOD2 agonist

CL429 is a chimeric compound that stimulates both TLR2 and NOD2. This compound is composed of murabutide (NOD2 ligand) covalently linked to Pam2C (TLR2 ligand) via a spacer.

CL429 was shown to induce synergistic human DC maturation in vitro and to significantly enhance both systemic and mucosal immunity against a vaccine antigen. The very potent adjuvant activity of CL429 is associated with no apparent toxicity. This activity seems to be mediated by an optimal DC maturation process, which induces strong B and T cell stimulation and autophagy.

CL429 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

CL429 VacciGrade™ is for research use only, not for use in humans.

Back to the top

Specifications

Description: TLR2 & NOD2 VacciGrade Agonist

Synonym: Pam2C-Aca-Benzyl-Murabutide

Formula: C74H128N6O17S

Molecular weight: 1405.90

Solubility: 5 mg/ml in DMSO

Quality: Sterile

Endotoxin Level: Lower than 1 EU/mg

Working concentration: 20 - 50 µg/mouse

Back to the top

Contents

CL429 VacciGrade ™ is provided as a sterile white lyophilized powder.

  • 5 mg CL429 VacciGrade™
  • 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

room temperature CL429 VacciGrade ™ is shipped at room temperature. 

store Store at -20°C.

stable Lyophilized product is stable for 1 year at -20°C.

Back to the top

Description

CL429 is a chimeric compound that stimulates both TLR2 and NOD2. This compound is composed of murabutide (NOD2 ligand) covalently linked to Pam2C (TLR2 ligand) via a spacer [1].

NOD2 is highly expressed at the mucosal level [2, 3] and its activation induces the production of proinflammatory cytokines and autophagy [4, 5].

TLR2 appears to have a special role in T cell polarization and differentiation [6], mucosal homing receptor expression, and IgA production by human B cells [7].

CL429 was shown to induce synergistic human DC maturation in vitro and to significantly enhance both systemic and mucosal immunity against a vaccine antigen [1].

The very potent adjuvant activity of CL429 is associated with no apparent toxicity. This activity seems to be mediated by an optimal DC maturation process, which induces strong B and T cell stimulation and autophagy [1].

 

1. Pavot V. et al., 2014. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity. J Immunol. 193(12):5781-5.
2. Geddes K. et al., 2009. Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov. 8(6):465-79.
3. Kobayashi KS. et al., 2005. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 307(5710):731-4.
4. Rubino SJ. et al., 2012. Nod-like receptors in the control of intestinal inflammation. Curr Opin Immunol. 24(4):398-404.
5. Cooney R. et al., 2010. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 16(1):90-7.
6. Borrello S. et al., 2011. TLR2: a crossroads between infections and autoimmunity? Int J Immunopathol Pharmacol. 24(3):549-56.
7. Liang Y. et al., 2011. Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clin Immunol. 138(1):33-40.

Back to the top

Citations

Load more

Customer Service
& Technical Support

Shopping cart is empty